Central Nervous System Biomarkers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Central Nervous System Biomarkers Market is Segmented by Type of CNS Biomarkers (Safety Biomarker, Efficacy Biomarker, Validation Biomarker, and Other Types of CNS Biomarkers), Application (Drug Discovery and Development, Personalized Medicine, and Other Applications), End User (Diagnostic Labs, Clinics/Hospitals, and Research Centers), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Central Nervous System Biomarkers Market Overview
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.5 %
Central Nervous System Biomarkers Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The central nervous system biomarkers market is projected to register a CAGR of 7.5% during the forecast period, with a revenue of approximately USD 4,652 million in 2020, and it is expected to reach USD 7,160 million by 2026.

COVID-19 cases across the world had a profound impact on the CNS biomarkers market. Based on the study “Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID‐19 and associated with neurological symptoms and disease severity” published in January 2021, various studies found that there was frequent reporting of neurological symptoms in patients hospitalized due to COVID-19. Thus, the researchers examined cerebrospinal fluid (CSF) from patients with neurological manifestations of COVID‐19 for biomarkers of the central nervous system (CNS) injury and other pathology in relation to neurological symptoms and disease severity. Therefore, future studies in larger samples are needed to explore and understand the genesis of neurological injury in COVID‐19 patients.

A biomarker is being used to measure the biological state, presence of diseases, and effects of treatments. The advancements in the fields of genomics and proteomics during the past decade have improved awareness regarding genetic regulatory pathways related to (central nervous system) CNS biomarkers. The proteomics technologies have advanced in various areas of drug discovery and development through a comparative assessment of normal and diseased tissues. The proteomics research has great potential in the discovery of relevant protein biomarkers in both diagnostics and therapies for the central nervous system. It plays a crucial role in earlier disease diagnosis, prognosis and in monitoring the central nervous disease development.

There is also an increasing number of pipeline studies for the development of biomarkers in various disease conditions, which is expected to boost the central nervous system biomarkers market growth. According to the study "Biomarkers in tumors of the central nervous system" published in 2019, specific diagnostic, prognostic, and predictive biomarkers were detected, and they continue to emerge. Hence, the knowledge of specific biomarkers is of great importance for individualized treatment and follow-up.

Therefore, the advanced imaging systems are aiding the early diagnosis of various diseases while reducing the mortality rate. The development in related technologies, such as genomics, proteomics, and imaging system, has reflected on the evolution of newer biomarkers. Considering the complexity of the central nervous system (CNS), biomarkers are now expected to play a significant role in the identification of several neurodegenerative diseases at an early stage, provide enhanced diagnosis, and eventually better treatment.

However, the high cost of CNS biomarker testing and diagnostics and certain issues related to regulatory and reimbursement systems are found to be the hindering factors impacting the growth of the market.

Scope of the Report

As per the scope of the report, central nervous system (CNS) biomarkers are used clinically to screen for, diagnose, or monitor the activity of CNS-related diseases to guide molecularly targeted therapy or assess therapeutic response. Biomarkers help in understanding the development of chronic diseases, their relationship with environmental chemicals, and identify subjects who are at high risk of developing diseases. The central nervous system biomarkers market is segmented by type of CNS biomarkers (safety biomarker, efficacy biomarker, validation biomarker, and other types of CNS biomarkers), application (drug discovery and development, personalized medicine and other applications), end user (diagnostic labs, clinics/hospitals, and research centers) and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

By Type of CNS Biomarkers
Safety Biomarker
Efficacy Biomarker
Validation Biomarker
Other Types of CNS Biomarkers
By Application
Drug Discovery and Development
Personalized Medicine
Other Applications
By End User
Diagnostic Labs
Research Centers
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Personalized Medicine Segment is Expected to Show Better Growth in the Forecast Period

Precision medicine or personalized medicine is found to be one of the most promising approaches to tackle various diseases. The major factors that are contributing to the growth of the market are the rising number of brain and other nervous system cancers. It has its rising application as a diagnostic tool, which helps in recognizing the precise biological markers. There is an increasing number of companies that are found focusing on developing breakthrough products for the treatment of neurological diseases.

The rising COVID-19 pandemic has impacted the personalized medicine segment. Precision medicine (PM) aims to tailor treatment and interventions to unique individual or population-level traits. Therefore, personalized medicine is relevant for addressing COVID-19 illness. The San Antonio Partnership for Precision Therapeutics (SAPPT) has also announced the funding of three projects that will accelerate treatments for COVID-19 using precision medicine principles.

Biomarker research in neurodegenerative disease is a rapidly advancing area in personalized medicine. The role of these markers is not only diagnostic, but they also have prognostic potential or role in the development of new treatment. Therefore, a large number of molecules have been evaluated and associated with different neurodegenerative disorders. Alzheimer’s disease and Parkinson’s disease are found to be the two most common neurodegenerative disorders.

This evolution within precision medicine has profoundly impacted the biopharmaceutical industry, and multiple players from biopharma to diagnostics companies with multiple functions such as research and development to commercial operations will witness a change. Therefore, all these factors have helped in boosting the overall market.

Central Nervous System Biomarkers Market Trends

North America Dominates the Central Nervous System Biomarkers Market

The growing burden of chronic diseases, rise in the development in proteomics, genomics, and imaging systems, and increasing adoption in personalized medicines and therapy are expected to drive the central nervous system (CNS) biomarkers market in the United States.

The increasing neurological symptoms have been frequently reported in hospitalized patients with COVID-19, and biomarkers of central nervous system (CNS) injury are reported to be increased in plasma but not extensively studied in cerebrospinal fluid (CSF). Therefore with the rising COVID-19 cases, there is increasing evidence of central nervous system (CNS) damage in COVID-19 patients by using serological biomarkers.

According to the estimates of the GLOBOCAN in 2020, there were an estimated 2,281,658 new cancer cases diagnosed and 612,390 deaths, due to cancer in the United States. The National Institute of Neurological Disorders and Stroke is mainly focusing on approaches that could facilitate the discovery and validation of robust biomarkers, primarily for better diagnosis and treatment of certain conditions. Hence, with the rising concerns regarding neurological disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.

The molecular biomarkers are used for various purposes, including CNS disease diagnosis, prognosis, prediction, and assessment of treatment response and safety. Almost every pharmaceutical company is formulating a molecular biomarker program, either alone or through partnerships. More molecular biomarkers are expected to be identified and validated in drug development.

In 2019, MC10 Inc. announced the collaboration with the University of Rochester for the development of novel digital biomarkers for central nervous system diseases. Hence, with the rising concerns regarding neurological disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.

Central Nervous System Biomarkers Market Growth

Competitive Landscape

The global players in the central nervous system biomarkers market include Acumen Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Aposense Ltd, Avacta Life Sciences Limited, Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., DiaGenic ASA, G-Biosciences, Merck KGaA, and Thermo Fisher Scientific Inc. The players strategically invest in the research and development for innovative and technological advancements and focus on partnerships with domestic players to expand their outreach.

Recent Developments

  • In November 2020, SomaLogic Inc. announced that it had successfully closed an Initial Series A capital raise of USD 121 million by leading life science investor Casdin Capita. The funds raised in this Series A round will be used in improving, expanding, and commercializing its proteomic products in both the clinical and life science markets.
  • In June 2020, Accure Therapeutics announced its opening, supported by EUR 7.6 million in the Series A funding. The Barcelona-based pharmaceutical company will focus on developing treatment candidates for central nervous system (CNS) disorders such as Parkinson’s disease.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in the Development in Proteomics, Genomics, and Imaging System

      2. 4.2.2 Rising Investments from Government and Private Players

      3. 4.2.3 Increasing Research and Development with Successful Clinical Trials of Biomarkers

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of CNS Biomarkers Tests and Diagnostics

      2. 4.3.2 Reimbursement and Regulatory Issues

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type of CNS Biomarkers

      1. 5.1.1 Safety Biomarker

      2. 5.1.2 Efficacy Biomarker

      3. 5.1.3 Validation Biomarker

      4. 5.1.4 Other Types of CNS Biomarkers

    2. 5.2 By Application

      1. 5.2.1 Drug Discovery and Development

      2. 5.2.2 Personalized Medicine

      3. 5.2.3 Other Applications

    3. 5.3 By End User

      1. 5.3.1 Diagnostic Labs

      2. 5.3.2 Clinics/Hospitals

      3. 5.3.3 Research Centers

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Acumen Pharmaceuticals Inc.

      2. 6.1.2 Alseres Pharmaceuticals Inc.

      3. 6.1.3 Aposense Ltd

      4. 6.1.4 Avacta Life Sciences Limited

      5. 6.1.5 Banyan Biomarkers Inc.

      6. 6.1.6 Bio-Rad Laboratories Inc.

      7. 6.1.7 DiaGenic ASA

      8. 6.1.8 G-Biosciences

      9. 6.1.9 Merck KGaA

      10. 6.1.10 Thermo Fisher Scientific Inc.

      11. 6.1.11 Abastar MDX Inc.

      12. 6.1.12 Adlyfe Inc.

      13. 6.1.13 Avid radiopharmaceuticals Inc.

      14. 6.1.14 Exonhit therapeutics

      15. 6.1.15 Proteome Sciences PLC

      16. 6.1.16 Enzo Biochem Inc.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Central Nervous System Biomarkers Market market is studied from 2018 - 2026.

The Global Central Nervous System Biomarkers Market is growing at a CAGR of 7.5% over the next 5 years.

The Global Central Nervous System Biomarkers Market is valued at 4652 Million USD in 2018.

The Global Central Nervous System Biomarkers Market is valued at 7160 Million USD in 2026.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Banyan Biomarkers Inc., Bio-Rad Laboratories, Inc., G-Biosciences, Merck KGaA, Thermo Fisher Scientific Inc. are the major companies operating in Global Central Nervous System Biomarkers Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!